HSPB1 Promotes Doxorubicin-induced Cardiomyocyte Pyroptosis by Inhibiting AATF
Abstract Background: Doxorubicin (DOX) has been widely used for the treatment of different kinds of cancers. However, the adverse effects, especially cardiotoxicity, which limit the long-term use of DOX. Although some signaling pathways have been investigated to be participated in DOX-induced cardiotoxicity, however, the mechanisms underlying DOX-induced cardiotoxicity need to be further investigated. Recent study suggested that heat shock proteins (HSPs) play a role in cell apoptosis and pyroptosis. However, we do not know yet whether heat shock protein beta-1 (HSPB1), a member of HSPs family, is involved in DOX-induced cardiomyocyte pyroptosis. This study aimed to evaluate the effects of HSPB1 and apoptosis antagonizing transcription factor (AATF) in DOX-induced pyroptosis in cardiomycytes.Results: We found that DOX remarkably enhanced the expression of HSPB1 but reduces AATF expression in cardiomyocytes. We also found that either inhibition of HSPB1 by small interfering RNA (siRNA) or overexpression of AATF by transfection of AATF plasmid significantly attenuated DOX-induced cardiomyocyte pyroptosis. Moreover, HSPB1 interacts with AATF. Furthermore, inhibition of HSPB1 and AATF restores the DOX-induced cardiomyocyte pyroptosis. Conclusion: Our findings reveal a novel pathway that cardiomyocyte pyroptosis is regulated through HSPB1-AATF-caspase-3-GSDME pathway following DOX treatment, suggesting that HSPB1-AATF-dependent pyroptosis may provide a novel therapeutic strategy to reduce cardiotoxicity induced by DOX.